{"qid":"Q001","question":"List key maternal and neonatal risks associated with gestational diabetes and briefly explain the pathway if known.","gold_claim_ids":["c0023","c0076","c0114"],"locked_answer":"Maternal risks include gestational hypertension/preeclampsia and increased cesarean delivery risk. Neonatal/fetal risks include macrosomia (large-for-gestational-age) with shoulder dystocia/birth trauma, neonatal hypoglycemia, preterm birth/respiratory distress, and longer-term offspring risk of obesity and type 2 diabetes. Pathway (core): maternal hyperglycemia crosses the placenta → fetal hyperinsulinemia → fetal overgrowth (macrosomia); after delivery maternal glucose supply stops while fetal insulin remains high → neonatal hypoglycemia.","variants":{"contradictory":"Maternal risks are reduced by gestational diabetes and neonatal risks are minimal; macrosomia is unrelated to maternal glucose. The fetus is protected because maternal glucose does not cross the placenta.","bad":"Gestational diabetes has no meaningful fetal risks and insulin is never used in management. Neonatal hypoglycemia does not occur after GDM pregnancies.","neutral":"Gestational diabetes is monitored during pregnancy, and risks depend on clinical context and follow-up.","entangled":"Maternal risks include preeclampsia and increased cesarean delivery risk; neonatal risks include macrosomia and neonatal hypoglycemia (maternal glucose crosses placenta → fetal hyperinsulinemia). Also, some studies note changes in breast milk composition timing in GDM (e.g., delayed attainment of certain milk components), which is a separate outcome not central to the main risk pathway."}}
{"qid":"Q002","question":"What diagnostic thresholds and testing approach are commonly used for diagnosing gestational diabetes with an OGTT?","gold_claim_ids":["c0110","c0122","c0190"],"locked_answer":"Common approach: a one-step 75 g oral glucose tolerance test (OGTT), typically used for universal screening/diagnosis in many guidelines. Example (ADA/IADPSG-style) diagnostic cutoffs for a 75 g OGTT: fasting ≥92 mg/dL (5.1 mmol/L), 1-hour ≥180 mg/dL (10.0 mmol/L), 2-hour ≥153 mg/dL (8.5 mmol/L). Diagnostic criteria vary somewhat across organizations, but OGTT is the core method.","variants":{"contradictory":"Common approach: a 50 g OGTT is the diagnostic test, and the key cutoff is a single 2-hour value ≥200 mg/dL; fasting and 1-hour values are not used.","bad":"HbA1c alone is sufficient for diagnosing gestational diabetes in pregnancy; OGTT is unnecessary.","neutral":"Gestational diabetes is diagnosed using glucose testing during pregnancy following clinical guidelines.","entangled":"Common approach: one-step 75 g OGTT with cutoffs such as fasting ≥92 mg/dL, 1-hour ≥180 mg/dL, 2-hour ≥153 mg/dL (criteria vary by guideline). Physiologically, pregnancy raises insulin resistance and beta cells normally increase insulin secretion to compensate; GDM occurs when compensation is insufficient (mechanism fact, not a threshold)." }}
{"qid":"Q003","question":"Explain why insulin resistance rises during pregnancy and what makes it become pathological in gestational diabetes.","gold_claim_ids":["c0140","c0176","c0087"],"locked_answer":"Insulin resistance rises progressively from mid-pregnancy into the third trimester due to increased maternal adiposity and placental hormone secretion (e.g., placental lactogen, progesterone, cortisol, prolactin, growth hormone). In normal pregnancy, pancreatic beta cells increase insulin secretion to maintain euglycemia. It becomes pathological (GDM) when beta-cell compensation is inadequate → maternal hyperglycemia.","variants":{"contradictory":"Insulin resistance decreases in pregnancy because placental hormones improve insulin sensitivity; GDM occurs mainly because insulin secretion is excessive, not because compensation fails.","bad":"Insulin resistance in pregnancy is usually diagnosed and confirmed by HbA1c alone; OGTT is not needed in pregnancy.","neutral":"Pregnancy changes metabolism and glucose regulation, and gestational diabetes occurs when regulation is impaired.","entangled":"Insulin resistance rises due to placental hormones and maternal adiposity; GDM occurs when beta cells can’t compensate → hyperglycemia. Hyperglycemia later in pregnancy is linked to fetal overgrowth/macrosomia (related consequence, beyond the core mechanism explanation)." }}
{"qid":"Q004","question":"After gestational diabetes, what is the longer-term cardiometabolic risk and what follow-up is recommended?","gold_claim_ids":["c0056","c0024","c0007"],"locked_answer":"Long-term risk: women with prior GDM have a substantially increased risk of developing type 2 diabetes later (commonly cited as a large fraction over 5–10 years; some guidance cites ~30–50% within ~10 years) and increased cardiometabolic risk factors/events. Recommended follow-up: postpartum glucose testing with a 75 g 2-hour OGTT at ~4–12 weeks after delivery (some sources also describe ≥6 weeks), then ongoing periodic diabetes screening (often annually or every 1–3 years, depending on guideline/risk).","variants":{"contradictory":"After GDM, long-term type 2 diabetes risk returns to baseline and no postpartum testing is recommended; if testing is done, a random glucose anytime in the first week postpartum is definitive.","bad":"Postpartum follow-up is unnecessary if symptoms improve, and HbA1c in the first few weeks postpartum is the preferred single test to rule out diabetes permanently.","neutral":"Follow-up after gestational diabetes is recommended based on clinical guidance and risk factors.","entangled":"Long-term risk includes progression to type 2 diabetes and higher cardiometabolic risk. Recommended follow-up includes a 75 g 2-hour OGTT at 4–12 weeks postpartum and periodic rescreening. Separately, during pregnancy glucose targets (fasting and postprandial) are used to guide management and fetal monitoring for macrosomia (true but not the postpartum question’s core)." }}
{"qid":"Q005","question":"In a low-risk pregnancy, what is the usual gestational age window for screening GDM, and what is the typical diagnostic test?","gold_claim_ids":["c0094","c0162","c0095"],"locked_answer":"In low-risk (universal) screening programs, GDM screening is typically done at 24–28 weeks’ gestation. A common diagnostic test is the 75 g oral glucose tolerance test (OGTT) (one-step approach in many guidelines).","variants":{"contradictory":"Low-risk pregnancies are typically screened at 6 weeks and again at 30 weeks, and HbA1c alone is the standard diagnostic test.","bad":"A single random glucose test in any trimester definitively diagnoses GDM; OGTT is not used.","neutral":"GDM screening is performed during pregnancy according to clinical guidance and local protocols.","entangled":"Typical screening in low-risk pregnancy is at 24–28 weeks, commonly with a 75 g OGTT. Criteria and thresholds vary across guidelines, which is one reason screening/diagnosis approaches are sometimes described as controversial." }}
{"qid":"Q006","question":"State an evidence-based clinical fact about diagnosis, monitoring, management, or outcomes of gestational diabetes.","gold_claim_ids":["c0073","c0005","c0122"],"locked_answer":"If lifestyle measures (diet/exercise) do not achieve glycemic targets in GDM, insulin is a standard first-line pharmacologic therapy because it does not cross the placenta and has an established safety record in pregnancy.","variants":{"contradictory":"If lifestyle measures fail, insulin is avoided in pregnancy because it readily crosses the placenta and harms the fetus.","bad":"Insulin is never used in gestational diabetes management, and medication is contraindicated in all cases.","neutral":"Gestational diabetes is managed with monitoring and treatment tailored to the patient.","entangled":"If lifestyle measures fail, insulin is a standard first-line medication because it does not cross the placenta. Many guidelines also emphasize fetal surveillance (e.g., ultrasound for growth/macrosomia) when control is poor or macrosomia is suspected (true but extra)." }}
{"qid":"Q007","question":"What postpartum follow-up testing is recommended after a pregnancy complicated by gestational diabetes?","gold_claim_ids":["c0171","c0083","c0194"],"locked_answer":"Recommended postpartum testing after GDM: a 75 g 2-hour OGTT at about 4–12 weeks postpartum (some sources describe ≥6 weeks postpartum). After the initial postpartum test, ongoing repeat diabetes screening is recommended periodically (often annually or every 1–3 years, depending on guideline/risk).","variants":{"contradictory":"Recommended postpartum testing is a 50 g glucose challenge test (GCT) at 1 week postpartum; no further screening is needed if normal.","bad":"No postpartum glucose testing is required after GDM because insulin sensitivity always normalizes permanently; future diabetes risk is negligible.","neutral":"Postpartum follow-up is recommended after gestational diabetes based on clinical guidance.","entangled":"Postpartum testing includes a 75 g 2-hour OGTT at 4–12 weeks (or ≥6 weeks) postpartum, with periodic rescreening later. Separately, breastfeeding has been associated with reduced later maternal type 2 diabetes risk (true but not itself a ‘test’)." }}
{"qid":"Q008","question":"Explain how insulin resistance rises during pregnancy and what makes it become pathological in gestational diabetes.","gold_claim_ids":["c0140","c0121","c0181"],"locked_answer":"Pregnancy increases insulin resistance from mid-pregnancy through the third trimester due to placental hormones and increased maternal adiposity. Normally, maternal beta cells increase insulin secretion to maintain normal glucose. GDM occurs when beta-cell compensation is insufficient → hyperglycemia.","variants":{"contradictory":"Pregnancy hormones reduce insulin resistance; GDM happens when beta cells overcompensate and create hypoglycemia.","bad":"GDM is diagnosed and explained primarily by HbA1c alone in pregnancy; placental hormones are not involved.","neutral":"Pregnancy affects insulin and glucose metabolism, and gestational diabetes occurs when regulation is impaired.","entangled":"Pregnancy hormones and maternal adiposity raise insulin resistance; beta cells normally increase insulin output. When compensation fails, GDM develops. Hyperglycemia can contribute to fetal overgrowth via fetal hyperinsulinemia (additional consequence beyond the mechanism)." }}
{"qid":"Q009","question":"What are the key maternal and neonatal risks associated with gestational diabetes and briefly explain the pathway if known.","gold_claim_ids":["c0023","c0076","c0122"],"locked_answer":"Maternal risks: gestational hypertension/preeclampsia and higher cesarean delivery risk. Neonatal/fetal risks: macrosomia with shoulder dystocia/birth trauma, neonatal hypoglycemia, preterm birth/respiratory distress, and longer-term offspring risk of obesity and type 2 diabetes. Pathway: maternal hyperglycemia crosses placenta → fetal hyperinsulinemia → macrosomia; after delivery, persistent fetal insulin → neonatal hypoglycemia.","variants":{"contradictory":"Gestational diabetes does not increase cesarean delivery or macrosomia risk; maternal glucose does not cross the placenta so fetal insulin levels are unaffected.","bad":"Insulin is never used for GDM, and neonatal hypoglycemia is not a recognized complication after GDM.","neutral":"GDM is monitored during pregnancy, and risks vary by individual factors and clinical care.","entangled":"Maternal risks include preeclampsia and increased C-section likelihood; neonatal risks include macrosomia and hypoglycemia via maternal glucose transfer → fetal hyperinsulinemia. Some literature also discusses altered colostrum immune composition in GDM (true but not the key risk pathway)." }}
{"qid":"Q010","question":"What diagnostic thresholds and testing approach are typically used for diagnosing gestational diabetes with an OGTT?","gold_claim_ids":["c0110","c0190","c0087"],"locked_answer":"Typically, diagnosis uses an OGTT (commonly a one-step 75 g OGTT). Example thresholds (ADA/IADPSG-style): fasting ≥92 mg/dL, 1-hour ≥180 mg/dL, 2-hour ≥153 mg/dL. Exact criteria can vary by guideline/region, but OGTT is central.","variants":{"contradictory":"Diagnosis typically uses a random glucose test without fasting or timed samples, and OGTT thresholds are not used in pregnancy.","bad":"HbA1c alone is sufficient for diagnosing GDM during pregnancy; OGTT is not recommended.","neutral":"Diagnosis relies on pregnancy glucose testing following local clinical guidelines.","entangled":"Diagnosis commonly uses a 75 g OGTT with cutoffs such as fasting ≥92 mg/dL, 1-hour ≥180 mg/dL, 2-hour ≥153 mg/dL (criteria vary). Separately, early pregnancy hyperglycemia is associated with increased congenital malformation risk, while later hyperglycemia is linked to fetal overgrowth (true but not a threshold answer)." }}
{"qid":"Q011","question":"List key maternal and neonatal risks associated with gestational diabetes and in one line, explain the pathway if known.","gold_claim_ids":["c0076","c0023","c0192"],"locked_answer":"Key risks: maternal preeclampsia/cesarean delivery; neonatal macrosomia, shoulder dystocia/birth trauma, neonatal hypoglycemia, preterm/respiratory distress; pathway: maternal hyperglycemia crosses placenta → fetal hyperinsulinemia → macrosomia, and post-delivery persistent insulin → neonatal hypoglycemia.","variants":{"contradictory":"Key risks are mainly reduced in GDM; maternal glucose does not cross the placenta so fetal insulin and growth are unaffected.","bad":"Insulin is never used in GDM management and neonatal hypoglycemia does not occur after GDM pregnancies.","neutral":"GDM is monitored and managed during pregnancy; risks depend on clinical context.","entangled":"Key risks include preeclampsia/C-section and neonatal macrosomia/hypoglycemia via maternal glucose transfer → fetal hyperinsulinemia. In some cohorts, GDM is also linked to higher long-term cardiometabolic risk in the mother (true but beyond the one-line request)." }}
{"qid":"Q012","question":"In a low-risk pregnancy, what is the typical gestational age window for screening GDM, and what is the typical diagnostic test?","gold_claim_ids":["c0094","c0095","c0162"],"locked_answer":"Typical universal screening window in low-risk pregnancy: 24–28 weeks’ gestation. Typical diagnostic test: 75 g oral glucose tolerance test (OGTT) (one-step approach in many guidelines).","variants":{"contradictory":"Typical screening is done at 6 weeks and 30 weeks, and HbA1c alone is the standard diagnostic test for GDM.","bad":"GDM is definitively diagnosed by a single random glucose test in any trimester; OGTT is unnecessary.","neutral":"Screening is performed during pregnancy according to clinical guidance and local policy.","entangled":"Universal screening is commonly at 24–28 weeks with a 75 g OGTT; high-risk patients may be screened earlier in pregnancy for overt diabetes (true but not the low-risk pathway)." }}
{"qid":"Q013","question":"Which postpartum tests are recommended after a pregnancy complicated by gestational diabetes?","gold_claim_ids":["c0107","c0174","c0083"],"locked_answer":"Recommended postpartum test after GDM: 75 g 2-hour OGTT at about 4–12 weeks postpartum (some sources describe ≥6 weeks). If normal, repeat diabetes screening periodically thereafter (often annually or every 1–3 years, depending on risk/guideline).","variants":{"contradictory":"Recommended postpartum test is a 50 g glucose challenge test at 1 week postpartum; if normal, no further screening is needed.","bad":"No postpartum testing is required after GDM because future diabetes risk is negligible.","neutral":"Postpartum testing after gestational diabetes is recommended according to clinical guidance.","entangled":"Postpartum testing includes a 75 g 2-hour OGTT at 4–12 weeks postpartum, with periodic rescreening later. Separately, lifestyle modification and weight management reduce progression risk after GDM (true but not a test)." }}

